Neuren Pharmaceuticals (NURPF) Stock Price, News & Analysis

Company Overview

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

Key Stats

• Today's Range: C$9.50 to C$9.50
• 50-Day Range: C$6.61 to C$10.33
• 52-Week Range: C$6.61 to C$17.21
• Volume: N/A
• Average Volume: 3,231 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Neuren Pharmaceuticals Stock Analysis - MarketRank™

Neuren Pharmaceuticals scored higher than 0% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Neuren Pharmaceuticals.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Neuren Pharmaceuticals is -1,062.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Neuren Pharmaceuticals is -1,062.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Neuren Pharmaceuticals has a short interest ratio ("days to cover") of 2779.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Neuren Pharmaceuticals has recently increased by 0.11%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neuren Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Neuren Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Neuren Pharmaceuticals has a short interest ratio ("days to cover") of 2779.7, which indicates bearish sentiment.

Change versus previous month

Short interest in Neuren Pharmaceuticals has recently increased by 0.11%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: N/A

News Sentiment

Neuren Pharmaceuticals has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Neuren Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 1.74% of the stock of Neuren Pharmaceuticals is held by institutions.

NURPF Stock Analysis - Frequently Asked Questions

How have NURPF shares performed this year?

Neuren Pharmaceuticals' stock was trading at C$16.98 on January 1st, 2024. Since then, NURPF shares have decreased by 44.1% and is now trading at C$9.50.
View the best growth stocks for 2024 here.

How do I buy shares of Neuren Pharmaceuticals?

Shares of NURPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:NURPF
• CUSIP: N/A
• CIK: N/A
• Web: www.neurenpharma.com
• Phone: (139) 092-0480
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A